IQVIA

Market Reflection Report

June 2022

11th July 2022

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM for the month with COVID portfolio is 13% while without
COVID portfolio is 18% TSA (Without Covid Molecule)
TSA (With Covid Molecule)
Growth %%

80 60
60 2019-20 40
40
2020-21 20
20
0 2021-22 0
-20 -20
Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun

TSA IPM Trends (Value Rs. 185,023 Crs) – MAT Jun'22 TSA IPM Trends (Value Rs. 172,686 Crs) – MAT Jun'22
Growth Over Previous Month – Jun'22 over May’22 0.79% Growth Over Previous Month – Jun'22 over May’22 0.62%

+13%
8% +16%
MAT MAT 12%
Month 185,023 Month
172,686
170,897
154,832
148,858
139,048 140,016
131,303

11,490 12,217 13,854 15,687 10,871 11,408 12,749 14,775

2019 2020 2021 2022 2019 2020 2021 2022

• IPM valued at Rs. 185,023 Cr with growth of 8% as of MAT Jun’22 and Rs 15,687 Cr for Jun’22 month with growth of 13%
• TSA without covid valued at Rs 172,686 Cr with 12% growth in MAT Jun’22 and 16% growth in Jun’22 Month

IQVIA TSA & SSA Dataset Jun'22 1

 While IPM at SSA is at 12% with Covid and w/o COVID is at
16% SSA (With Covid Molecule) SSA (Without Covid Molecule)
60 60
Growth %%

40 40

20 20

0 0

-20 -20
Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar Apr May Jun

SSA IPM Trends (Value Rs. 156,824 Crs) – MAT Jun'22 SSA IPM Trends (Value Rs. 146,581 Crs) – MAT Jun'22
Growth Over Previous Month – Jun'22 over May’22 0.58% Growth Over Previous Month – Jun'22 over May’22 0.43%

+12% 15%
8% MAT MAT 11%
Month Month
156,842 146,581
145,429 132,486
126,560 119,059
117,602 111,068

9,678 10,565 11,793 13,235 9,157 9,877 10,893 12,476

2019 2020 2021 2022 2019 2020 2021 2022

• IPM valued at Rs. 156,824 Cr with growth of 8% as of MAT Jun’22 and Rs 13,235 Cr for Jun’22 month with growth of 12%
• SSA without covid valued at Rs 146,581 Cr with 11% growth at MAT Jun’22 level, whereas growth of 15% at Jun’22 Month level

IQVIA TSA & SSA Dataset Jun'22 2

 Pain, Gastro, AI, Resp continue to drive growths
MTH (Val in Crs) MTH Growth% MAT (Val in Crs) MAT Growth%

1,937 10 22,424 6
CARDIAC CARDIAC
1,848 12 21,312 8

1,609 19 20,828 9
AI AI
1,522 24 19,380 12

1,795 20 19,587 12
GASTRO GASTRO
1,795 20 19,587 12

1,489 8 17,139 6
ANTI DIAB ANTI DIAB
1,489 8 17,139 6

1,068 18 15,647 22
RESPI RESPI
820 24 12,204 24

1,324 7 14,870 3
VMN VMN
961 15 10,540 9

1,256 25 14,478 15
PAIN PAIN
1,237 25 14,280 16

1,094 2 13,179 5
DERMA DERMA
1,071 8 12,784 9

344 32 3,638 13
ANTINEOPLAST ANTINEOPLAST
327 35 3,441 24

236 14 2,804 6
HORMONES HORMONES
184 16 2,094 10

81 -47 1,256 -66

ANTIVIRAL ANTIVIRAL
76 -7 834 -11

3
IQVIA TSA & SSA Dataset Jun'22 With Covid Without Covid
 Pain followed by Gynae posted highest growth in top 10
therapies for Jun’22
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)
16 19 21
13 10 12 10 13
4 5 IPM
IPM 15,687 -9 -6
8 9 7 12 7 10 8 10
6 5
CARDIAC 1,937 -4 -4 CARDIAC

18 17 10 11 17 11 15 9 8 12 20
GASTRO 1,795 3 GASTRO
34 50
30 28 21 17 13 19
4 -6 AI
AI 1,609 -30 -28
8 10 9 8
6 6 6 5 7
ANTI DIABETIC 1,489 1 3 1 ADB
11 12 16
3 9 7 6 7
1 2 VMN
VMN 1,324 -14 -14
21 28 19 16 19 14 28 25
4 8 -2 11
1,256 PAIN
PAIN
14 12
4 3 6 4 2 6 5 1 2 DERMA
-3
DERMA 1,094 86
50 58 36
28 24 33 16 11 18
-24 RESP
RESPIRATORY 1,068 -30
12 16 15 15 14
11 10 8 9 9 9
4 NEURO
NEURO 963
23 23 17 20 29 21
15 9 11 9 3 10
GYNAE
GYNAEC. 867
Jul Aug Sep Oct Nov Dec Jan Feb Feb Apr May Jun

Therapy sorted on Month

IQVIA TSA & SSA Dataset Jun'22 4
 Top Companies #1-10 Market Share Trend
9

Val Jun’22 MS Jun’22

8 (SUN*) 1228.4 7.83
ABBOTT* 999.9 6.37
7 CIPLA 789.7 5.03
MANKIND 669.3 4.27
(ALKEM*) 628.9 4.01
6
(LUPIN) 554.5 3.53
INTAS* 547.6 3.49
5
TORRENT 538.2 3.43
(MACLEODS) 489.8 3.12
4 (DRL) 465.1 2.96

2
Jun’21 Jul’21 Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22

• Abbott*, Cipla, Mankind, Intas* & Torrent has shown improvement in MS for Jun’22 as compared to May’22
• Sun*, Alkem* , Lupin, Macleods & DRL show a dip in MS in Jun’22 as compared to May’22

IQVIA TSA & SSA Dataset Jun'22 5

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth Gr% w/o COVID Value (Rs. Crs) % Gwth Gr% w/o COVID

SUN* 1,228 18 20 SUN* 1,047 16 18

ABBOTT* 1,000 18 22 ABBOTT* 856 17 21
CIPLA 790 15 18 CIPLA 666 17 18
MANKIND 669 12 14 MANKIND 604 12 14
Month

Month
ALKEM* 629 20 22 ALKEM* 543 19 21
LUPIN 554 12 13 LUPIN 477 10 12
INTAS* 548 22 24 TORRENT 474 20 20

TORRENT 538 21 21 INTAS* 444 19 21

MACLEODS 490 17 19 MACLEODS 432 16 17

4 6 DRL 398 1 4
DRL 465

SUN* 14,128 12 13 SUN* 12,124 11 12

ABBOTT* 11,450 10 12 ABBOTT* 9,761 9 11
CIPLA 9,606 2 10 CIPLA 8,034 6 11
MANKIND 7,862 10 11 MANKIND 7,079 9 10
MAT

14 13

MAT
ALKEM* 7,245 13 ALKEM* 6,325 12
LUPIN 6,561 8 9 LUPIN 5,692 8 9
INTAS* 6,138 15 15 TORRENT 5,258 10 10
TORRENT 5,949 11 11 MACLEODS 5,257 13 15
MACLEODS 5,891 14 16 INTAS* 5,048 13 14
DRL 5,668 7 11 DRL 4,917 8 10

• TSA: Intas posted highest growth for the month followed by Torrent while for MAT, Intas* followed by Macleods posted highest growth

• SSA: Torrent followed by Intas* & Alkem* showed highest growth for Jun'22 while for MAT, Intas followed by Macleods posted highest growth

6
IQVIA TSA & SSA Dataset Jun'22
 Top Companies #11-20 Market Share Trend
3.4

3.2
Val Jun’22 MS Jun’22
3.0
(ZYDUS*) 440.7 2.81
2.8 (ARISTO*) 434.2 2.77
2.6 GSK* 376.4 2.40
2.4 (EMCURE*) 319.4 2.04
2.2 USV 316.4 2.02
2.0 GLENMARK 308.1 1.96
IPCA 287.5 1.83
1.8
(PFIZER*) 278.6 1.78
1.6
(SANOFI*) 257.1 1.64
1.4
(MICRO*) 255.7 1.63
1.2

1.0

0.8

0.6
Jun’21 Jul’21 Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22

• GSK*, USV & Glenmark have shown improvement in MS in Jun’22 as compared to May’22
• IPCA has maintained its MS for the month of Jun’22
• Zydus*, Aristo*, Emcure*, Pfizer*, Sanofi* & Micro* have shown a dip in MS in Jun’22 as compared to May’22
.

IQVIA TSA & SSA Dataset Jun'22 7

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth Gr% w/o COVID Value (Rs. Crs) % Gwth Gr% w/o COVID

11 13 ARISTO* 393 22 23
ZYDUS* 441
23 23 ZYDUS* 360 11 13
ARISTO* 434
7 7 GSK* 298 5 5
GSK* 376
7 12 USV 283 12 13
EMCURE* 319
Month

Month
10 11 GLENMARK 267 4 11
USV 316
4 11 EMCURE* 263 10 14
GLENMARK 308
31 31 IPCA 246 29 29
IPCA 287
2 5 MICRO * 217 9 10
PFIZER* 279
3 4 PFIZER* 214 3 7
SANOFI* 257
9 9 ALEMBIC 196 13 16
MICRO * 256

ARISTO* 5,393 11 12 ARISTO* 4,897 11 11

ZYDUS* 5,376 6 12 ZYDUS* 4,378 6 11
GSK* 4,773 7 7 GSK* 3,808 7 7
GLENMARK 3,890 -10 12 GLENMARK 3,399 -10 12
MAT

12 8 9

MAT
EMCURE* 3,855 6 USV 3,164
USV 3,561 7 8 EMCURE* 3,125 8 13
PFIZER* 3,455 0 4 IPCA 2,893 15 16
IPCA 3,346 16 18 PFIZER* 2,674 -1 4
MICRO * 3,176 18 19 MICRO * 2,653 16 17
SANOFI* 3,121 3 4 ALEMBIC 2,528 10 16

• TSA & SSA: IPCA posted highest growth for the month followed by Aristo*, for MAT, Micro* followed by Ipca posted highest growth

IQVIA TSA & SSA Dataset Jun'22 8

 Top Companies #21-30 Market Share Trend
1.8
Val Jun’22 MS Jun’22
1.7
(ALEMBIC) 219.6 1.40
1.6 (FDC) 158.8 1.01
1.5 (JB PHARMA*) 150.5 0.96
1.4 HIMALAYA 141.9 0.90
(ERIS*) 136.0 0.87
1.3
(CADILA) 122.7 0.78
1.2
(AJANTA) 117.6 0.75
1.1
(FRANCO) 111.7 0.71
1.0 INDOCO* 100.3 0.64
0.9 LA RENON 95.1 0.61

0.8

0.7

0.6

0.5
Jun’21 Jul’21 Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22

• Himalaya & Indoco* have shown improvement in MS for Jun’22 as compared to May’22
• La Renon has maintained its MS for the month of Jun’22
• Alembic, FDC, JB Pharma*, Eris*, Cadila, Ajanta & Franco have shown a dip in MS for Jun’22 as compared to May’22

IQVIA TSA & SSA Dataset Jun’22 9

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth Gr% w/o COVID Value (Rs. Crs) % Gwth Gr% w/o COVID

17 SANOFI* 194 1 3
ALEMBIC 220 15
27 FDC 146 27 29
FDC 159 26
21 22 JB PHARMA* 134 20 21
JB PHARMA* 150
9 10 HIMALAYA 128 8 9
HIMALAYA 142
Month

Month
12 13 ERIS* 114 7 9
ERIS* 136
8 10 AJANTA 104 17 17
CADILA 123
19 19 FRANCO 104 0 -1
AJANTA 118
1 1 CADILA 99 3 4
FRANCO 112
14 16 INDOCO* 91 13 14
INDOCO* 100
36 34 BLUE CROSS 82 11 13
LA RENON 95

ALEMBIC 2,793 12 17 SANOFI* 2,385 2 3

FDC 1,823 8 11 FDC 1,672 7 10
JB PHARMA* 1,630 23 23 JB PHARMA* 1,441 23 23
HIMALAYA 1,583 -2 1 HIMALAYA 1,423 -2 0
MAT

10 6 8

MAT
ERIS* 1,566 8 ERIS* 1,356
CADILA 1,440 5 6 FRANCO 1,256 0 0
FRANCO 1,345 1 1 AJANTA 1,193 15 14
AJANTA 1,338 16 16 CADILA 1,180 1 2
INDOCO* 1,224 9 12 INDOCO* 1,113 8 11
BLUE CROSS 1,145 12 15 BLUE CROSS 1,049 12 15

• TSA: La Renon has posted highest growth for the month while for MAT JB Pharma has posted highest growth followed by Ajanta
• SSA: FDC is the fastest growing company for the month, for MAT JB Pharma is the fastest growing company followed Ajanta

IQVIA TSA & SSA Dataset Jun'22 10

 Top Companies #31-40 Market Share Trend
0.72 Val Jun’22 MS Jun’22
0.70
BLUE CROSS 90.9 0.58
0.68
0.66 (P&G HLTH) 89.3 0.57
0.64 (NOVARTIS*) 88.9 0.57
0.62 MEDLEY 86.5 0.55
0.60
(CORONA) 83.8 0.53
0.58
SYSTOPIC 79.8 0.51
0.56
0.54 HETERO* 76.5 0.49
0.52 WIN MEDICARE 71.6 0.46
0.50 (JANSSEN) 70.5 0.45
0.48
H&H 70.2 0.45
0.46
0.44
0.42
0.40
0.38
0.36
Jun’21 Jul’21 Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22

• Hetero*, Win Medicare & H&H have improved MS in Jun’22 as compared to May’22
• Blue Cross, Medley & Systopic have maintained its MS for the month of Jun’22
• P&G Health, Novartis*, Corona & Janssen have shown dip in MS in Jun’22 as compared to May’22

IQVIA TSA & SSA Dataset Jun'22

11
 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth Gr% w/o COVID Value (Rs. Crs) % Gwth Gr% w/o COVID

BLUE CROSS 91 12 15 MEDLEY 82 12 13

P&G HLTH 89 11 13 P&G HLTH 81 10 12
NOVARTIS* 89 11 11 LA RENON 77 36 35
MEDLEY 86 11 12 SYSTOPIC 71 10 11
Month

Month
CORONA 84 22 21 CORONA 71 23 23
SYSTOPIC 80 11 12 NOVARTIS* 69 7 7
HETERO* 77 1 38 WIN MEDICARE 61 10 10
WIN MEDICARE 72 12 13 H&H 61 16 15
JANSSEN 71 40 40 HETERO* 60 4 33
H&H 70 20 19 APEX 56 -1 26

P&G HLTH 1,079 8 7 P&G HLTH 993 7 7

LA RENON 1,038 33 30 MEDLEY 890 5 6
NOVARTIS* 1,004 -4 -4 SYSTOPIC 840 8 8
HETERO* 967 -8 20 LA RENON 834 34 31
MAT

6 20 21

MAT
MEDLEY 950 5 CORONA 789
CORONA 938 18 20 HETERO* 786 -2 17
SYSTOPIC 936 9 9 NOVARTIS* 781 -3 -3
BHARAT SERUM 833 12 11 H&H 730 12 11
H&H 830 14 13 WIN MEDICARE 716 -1 -2
WIN MEDICARE 827 -1 -1 APEX 677 -8 19

• TSA: Janssen shows the highest growth for the month followed by Corona while for MAT La Renon has posted highest growth
• SSA: La Renon has posted highest growth followed by Corona for the month as well as for MAT

IQVIA TSA & SSA Dataset Jun'22 12

 Top Companies #41-50 Market Share Trend
0.55
Val Jun’22 MS Jun’22
BOEHRINGER 63.8 0.41
0.50 BHARAT SERUM 63.3 0.41
MEYER 62.5 0.40
0.45
APEX 62.1 0.40
(RAPTAKOS) 62.0 0.40
(WALLACE) 61.0 0.39
0.40 FOURRTS 60.0 0.39
MSD* 58.8 0.38
(PHARMED) 50.4 0.32
0.35
SAMARTH 48.2 0.31

0.30

0.25
Jun’21 Jul’21 Aug’21 Sep’21 Oct’21 Nov’21 Dec’21 Jan’22 Feb’22 Mar’22 Apr’22 May’22 Jun’22

• Boehringer, Bharat Serum, Meyer, Apex & Samarth have shown improvement in MS for Jun’22 as compared to May’22
• Fourrts & MSD* have maintained MS in the month of Jun’22
• Raptakos, Wallace, & Pharmed reflected dip in MS for Jun’22 as compared to May’22

IQVIA TSA & SSA Dataset Jun'22 13

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth Gr% w/o COVID Value (Rs. Crs) % Gwth Gr% w/o COVID

WALLACE 55 14 15
BOEHRINGER 66 1 3
BOEHRINGER 55 -3 -2
BHARAT SERUM 66 5 5
RAPTAKOS 55 10 14
MEYER 64 9 10
MEYER 54 8 9
APEX 63 1 31
Month

Month
FOURRTS 53 2 8
RAPTAKOS 62 12 16
BHARAT SERUM 48 0 1
WALLACE 62 15 16
JANSSEN 48 19 19
FOURRTS 61 3 10
MSD* 46 -14 -7
MSD* 61 -15 -7
PIRAMAL* 41 12 13
PHARMED 47 28 30
PHARMED 40 26 28
SAMARTH 47 11 15

MSD* 788 -17 -7 FOURRTS 656 6 9

BOEHRINGER 761 -2 0 WALLACE 644 8 9
APEX 760 -7 20 BOEHRINGER 641 -3 -2
FOURRTS 754 7 10 MEYER 626 9 10
MAT

8 10

MAT
JANSSEN 752 25 25 BHARAT SERUM 613
MEYER 732 9 10 MSD* 597 -19 -7
WALLACE 715 8 9 RAPTAKOS 581 -4 -3
RAPTAKOS 653 -3 -1 JANSSEN 550 13 13
CENTAUR 578 15 15 CENTAUR 543 14 14
DABUR 573 -3 4 PIRAMAL* 466 2 3

• TSA: Pharmed is the fastest growing company for the month and Janssen has posted the highest growth for MAT

• SSA: At month level, Pharmed is the fastest growing company followed by Janssen while for MAT, Centaur has posted highest growth

IQVIA TSA & SSA Dataset Jun'22 14

 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

4 0.46 0.21
MIXTARD 72 JANUMET 32 -4
16 0.41 0.20
GLYCOMET-GP 64 ACILOC 32 29
33 0.35 0.20
FORACORT 55 MANFORCE 32 30
Top 1-10

Top 21-30
0 0.33 0.20
LANTUS 52 BECOSULES 31 9
25 0.32 0.20
LIV-52 51 TELMA 31 26
34 0.30 0.19
AUGMENTIN 47 MIKACIN 30 50
43 0.30 0.19
PAN 46 CALPOL 30 -5
25 0.29 0.19
THYRONORM 46 RANTAC 30 39
14 0.27 0.19
BETADINE 42 LEVIPIL 29 12
-4 0.27 0.19
DEXORANGE 42 VOLINI 29 0
0.26 29 52 0.19
MONOCEF 40 40 ELECTRAL
PAN-D 39 35 0.25 DUOLIN 28 51 0.18
0.24 -20 0.18
Top 11-20

NOVOMIX 38 5 ZINCOVIT 28

Top 31-40
SHELCAL 37 24 0.24 SEROFLO 28 29 0.18
UDILIV 37 21 0.23 ROSUVAS 28 23 0.18
CLAVAM 36 14 0.23 ECOSPRIN-AV 27 24 0.17
ZERODOL-SP 35 42 0.22 BUDECORT 26 68 0.17
RYZODEG 34 42 0.22 AZITHRAL 26 18 0.17
DUPHASTON 34 17 0.21 PANTOP 26 24 0.17
ULTRACET 33 38 0.21 GEMER 26 16 0.17

• Mixtard remains the topmost brand with 72 Crs of sales & MS of ~0.46% for the month

• Among top 10 brands Pan has shown highest growth followed by Augmentin for the month

IQVIA TSA & SSA Dataset Jun'22 15

 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Jun'22 (in comparison to May’22), among the
Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• IPCA, Sanofi* & Himalaya gained 1 rank each to reach 17th ,
19th & 24th position
• Emcure* improved by 2 ranks to reach 18th position
In the month of Jun'22 (in comparison to May’22), among
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Glenmark gained 1 rank to reach 15th position
• Micro* improved by 2 ranks to reach 18th position

As per MAT Jun'22 (in comparison to May’22) among the

As per MAT Jun'22 (in comparison to May’22) among the Top Top 25 companies
25 companies • Sun* has maintained its top position in the IPM with a market
• Sun* has maintained its top position in the IPM with a market share of 8%
share of 8% • Torrent* & Micro* gained 1 rank each to reach 7th & 19th
• Aristo* & Micro* gained 1 rank each to reach 11th & 19th positions, respectively
positions, respectively

IQVIA TSA & SSA Dataset Jun’22 16

 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Jun'22 Month (in comparison to May’22 Month)
• Mixtard ranks No 1 position at month level
• Amongst the top 10 Brands, Pan grew at 43% followed by Augmentin with a growth of 34%
• Foracort & Udiliv gained 1 rank to secure 3rd & 15th position respectively with a growth of 33% & 21% respectively
• Pan-D & Ryzodeg 2 ranks to secure 12th &18th position with a growth of 35% & 42% respectively
• Liv-52, Betadine & Janumet gained 3 ranks to secure 5th ,9th & 21st position respectively with a growth of 25%, 14% & -4%
respectively
• Augmentin & Manforce gained 4 ranks to secure 6th & 23rd position with a growth of 34% & 30% respectively
• Becosules gained 6 ranks to secure 24th position with a growth of 9%
• Shelcal gained 7 ranks to secure 14th position with a growth of 24%
• Zerodol-SP gained 8 ranks to secure 17th position with a growth of 42%

IQVIA TSA & SSA Dataset Jul’21

IQVIA TSA & SSA Dataset Jun'22 17
 Indian / MNC trends % Growth Over Same Month Last Year
25 23
20 Indian
20 17 14
14 MNC
15 13 14
11 11
14 10
Month Growth

10 8
11 7 5
5 4 4
5 2
1
0
-6
-5 -8
-10
-10
JUL’21 AUG’21 SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22

Value (Rs. Crs)

Indian MNC

15,378 16,019 16,546 15,774 15,129 15,171 16,009 13,439 14,351 15,955 15,564 15,687
Share in IPM

12,644 13,209 13,703 13,036 12,421 12,452 13,252 11,033 11,736 13,125 12,809 12,934

2,734 2,810 2,843 2,738 2,708 2,718 2,757 2,406 2,615 2,831 2,754 2,754

JUL’21 AUG’21 SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22

• Indian companies has registered growth of 14% whereas MNC’s registered a growth of 10% for the month

IQVIA TSA & SSA Dataset Jun'22 18

 Acute / Chronic Trends
30 27
25 20 22 ACUTE
20 15 CHRONIC
14 1412 13 13
15 10 10 11
10 10
Growth (%)

9
10 9 5
5 2 1 2
3
0
-5
-11
-10 -15
-15
JUL’21 AUG’21 SEP’21 OCT’21 NOV’21 DEC’21 JAN’22 FEB’22 MAR’22 APR’22 MAY’22 JUN’22

Gwth %
8% 8% 2% 28% 9%
Top 5 TC 4s

263
Value (Rs 196
167 160 139
Crs)

GLIMEPIRIDE+METFORM. INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS AMOXY. & CLAV. SOLIDS COUGH PREP. ETHICALS

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 64 ABBOTT* 144 APEX 29 GSK* 35 GLENMARK 22

LUPIN 28 LUPIN 26 ALKEM 26 ALKEM* 27 DRL 22

SUN* 26 CIPLA 10 SUN* 24 MANKIND 20 FRANCO 13

• Acute as well as Chronic therapy has shown growth of 13% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Jun'22 19
 Top Therapy Trends
TSA

Value_JUN'22 (Rs. Crs) % Gwth SPLY Value_JUN'22 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 101 18 J01C0G AMOXY. & CLAV. SOLIDS 160 28

C02C04 TELMISARTAN 86 13 J01D0C CEFTRIAXONE INJECTABLS 101 44

5 J01N01 MEROPENEM 94 6

Anti-Infectives
C10A03 ATORVASTATIN 75
C02F06 AMLODIPINE+TELMISARTAN 72 18 J01D0L CEFIXIME ORAL SOL. 70 33
Cardiac

C02G0H TELMISARTAN + HCT 65 12 J01K03 AMIKACIN 68 54

B01A0E ENOXAPARIN 56 -17 J01D0I CEFUROXIME ORAL SOLIDS 65 23

C01E03 METOPROLOL 55 7 J01F04 AZITHROMYCIN ORAL SOLIDS 63 2

C02F02 ATENOLOL+AMLODIPINE 51 -3 J01C0H AMOXY. & CLAV. LIQUIDS 60 80

C01D0B CILNIDIPINE 49 14 J01D0Z CEFTRIAXONE+SULBACTAM 59 36

C02F0I METOPROLOL+TELMISARTAN 48 20 J01K05 PIPERACILLIN+TAZOBACTAM 55 6

A02B0Q PANTOPR.+ DOMPERID. 125 23 A10B0Q GLIMEPIRIDE+METFORM. 263 8

A02B0R RABEPRA.+ DOMPERID. 97 10 A10C03 INTER.-ACTING+FAST ACTING 196 8
A02B0A PANTOPRAZOLE SOLIDS 91 24 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 94 9
48

Anti Diabetic
A07L01 ORAL ELECTROLYTES 74 A10C05 LONG ACTING 88 7
A07K09 OTHERS 58 27 A10B0D METFORMIN + VILDAGLIPTIN 83 17
GI

A02B01 RANITIDINE ORAL SOLIDS 56 30 A10C01 FAST ACTING 65 2

A09A02 DIGEST. INC. ENZYME LIQUIDS 53 4 A10B0W PIOGLITAZ.+METFORM.+GLIM. 61 6
A02B0S ESOMEPR.+ DOMPERID. 52 23 A10B07 METFORMIN + SITAGLIPTIN 56 1
A02A05 ANTACID+ANTIFLATU.LIQ 47 1 A10B0O METFORMIN + TENELIGLIPTIN 53 -3
A06A07 MILK OF MAG AND COMB. 45 17 A10B12 DAPAGLIFLOZIN 42 30

• In Cardiac, metoprolol+telmisartan posted highest growth of 20%

• In AI, amoxy. & clav. liquids has posted 80% growth which is highest amongst top therapy
• Pantopr.+ Domperid.is the top contributing subgroup in GI therapy value around 125 Cr
• In Anti diabetic, dapagliflozin subgroup has posted highest growth of 30%

IQVIA
IQVIA TSA &TSA & SSA
SSA Dataset Dataset
Jun'22 Aug’21 20
 Top Therapy Trends
TSA

Value_JUN'22 (Rs. Crs) % Gwth SPLY Value_JUN'22 (Rs. Crs) % Gwth SPLY

V06E01 FOOD SUPPLEMENTS 167 2 R05B01 COUGH PREP. ETHICALS 139 9

A12A04 CALCIUM + COLECALCI. SOLI. 102 17 R03C0R FORMOTERAL+BUDESONIDE 87 20

RESPIRATORY
A11F02 MECOBALAMIN COMB. 99 12 R03B01 LEVOCETIRIZ.+MONTELU SOLD 75 11

A11C02 PLAIN VIT.D 78 11 R05A02 COLD PREP. LIQUIDS 56 58

94
VMN

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 72 3 R05B03 CODEINE AND COMB. 50

V06C01 INFANT FORMULAS 69 21 R05B05 LEVOSALBUTAMOL & COMB. 44 55

A15A01 APPETITE STIMULANTS 52 6 R03C0P SALMETEROL+FLUTICASONE 36 19

A12A01 CALCIUM ORAL SOLIDS 45 26 R03C0S IPRATROPIUM + LEVOSALBU. 34 46

V06E05 ADULT WELLNESS 41 -8 R05A01 COLD PREP. SOLIDS 32 42

A11E0C WITH VIT.C SOLIDS 40 14 R03C02 BUDESONIDE 31 68

M02A01 NSAIDS 81 7 D02A01 EMOLLIENTS,PROTECTIVES 98 14

M05C02 CALCITRIOL COMB. 74 16 D01C03 ITRACONAZOLE 74 -11
M01A0G PARACE.+ACECLOF.+SERRAPE. 60 35 D11A09 OTH.DERMATOLOGICAL PREP. 54 23
N02B05 PARACETAMOL ORAL SOLIDS 54 -9 D01A02 LULICONAZOLE 37 -7

Derma
N02B0K PARACETAMOL + TRAMADOL 45 33 D06A08 MUPIROCIN 35 37
Pain

N02B06 PARACETAMOL ORAL LIQUIDS 42 60 D07D0C CLOBET+MICONAZOL+NEOMYCIN 30 -2

M05B0C COLLAGEN COMB 40 58 D02B01 SUNSCREENS 29 78
M01A0U ACECLOFENAC + PARACETAMOL 39 20 D01A04 CLOTRIMAZOLE 28 7
N02B07 PARACETAMOL INJECTIONS 39 84 D02C07 HYDROQU.+TRETI.+MOMETA. 27 0
M01A03 DICLOFENAC INJECTABLES 35 35 D16A0D OTH HAIR CARE PREPS. 26 5

• In VMN therapy, food supplements is the top contributing subgroup with 167 Cr of sales posted growth of 2%
• In Respiratory market, cough prep is observed to be top contributing one with 139 Cr of sales posted growth of 9%
• In Pain market, paracetamol oral solids, liquids & inj contributed ~ 134 Crs of sales with -9% ,60% & 84% growth, respectively
• Emollients protectives registered highest sales of 98 Cr in derma market with 14% growth while the highest growth of 78% is observed in sunscreens

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Jun'22 21
Top Therapy Trends
TSA

Value_JUN'22 (Rs. Crs) Value_JUN'22 (Rs. Crs) % Gwth SPLY

% Gwth SPLY
11 B03A01 CONV.IRON SOLIDS 121 11
N03A0T LEVETIRACETAM 78
7 B03A02 CONV.IRON LIQUID 113 5
N06C02 ESCITALOPRAM+CLONAZEPAM 38
16 G03D04 DYDROGESTERONE 81 91
N07C01 BETAHISTINE 34
41 73 10
Neuro / CNS

G03D03 PROGESTERONE

Gynaec.
N03A0V GABAPENTIN + NORTRIPTYLIN 33
13 B03A03 CONV.IRON INJ. 66 28
N07A02 PREGABALIN+MECOBALAMIN 26
31 G03K02 MIFEPRISTONE+MISOPROSTOL 35 -13
N07A01 PREGABALIN 25
15 G02C01 OTHER GYNAECO.PREP. 32 14
N03A0J OXCARBAZEPINE 24
1 G03G06 HUMAN MENOPAUSAL GONADOTROP. 27 86
N03A04 SODIUM VALPROATE ORAL SOLIDS 24
26 G03G05 HUMAN CHORIONIC GONADOTROP. 25 20
N03A0I NORTRIPTYLINE+PREGABALIN 24
0 G03D02 NORETHISTERONE 21 20
N03A0D CLONAZEPAM 19

• In Neuro therapy, levetiracetam is the top valued subgroup with 78 Crs of sales and 11% of growth
• In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~300 Cr of sales to the entire therapy
• Among the top gynae Therapies, Human Menopausal Gonadotrop. has posted highest growth of 86%

IQVIA
IQVIA TSATSA
& SSA&Dataset
SSAJun'22
Dataset Aug’21 22
 Key changes
PTR Changes (Top 50 brands) New Introduction

➢ 452 new packs were Introduced in Jun’22

➢ Total number of SKUs with PTR changes in Jun’22 is 2248
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Betadine, Foracort, Pan, Clavam, Azithral, Duolin, Brand Transfer
Shelcal, Becosules, Seroflo, Ceftum, Rosuvas, Budecort, T-bact,
Gluconorm-G & Taxim-O.
➢ 6 brand transfer from Dr. Reddys Lab to Torrent Pharma in Jun’22

➢ 2 brand transfer from Reckitt Benckiser to Brinton Pharma in Jun’22

➢ 4 brand transfer from Unident Manufact to Encube Ethicals in Jun’22

New Lab & Corporate
Covid Molecules Details

Antisep. Disinfect.,Immunity Boosters, Ethical, Methylprednisolone, Levocet

➢ Apple Lifescience, Cureill Pharma, Encube Ethicals & Eysys Pharma + Montelukast, Azithromycin, Hydroxychloroquine, Prednisolone,
were introduced in Jun’22 dataset Enoxaparin,Formo + Bude,Doxycycline,Amphotericin B, Oseltamivir,
Anticoagulants, Itolizumab, Pirfenidone, Dexamethasone,
Budesonide,Acebrophy + Acetyl,Bevacizumab, Ivermectin,
Market Restatement
Nintedanib,Ipratrop + Levosal, Posaconazole, Favipiravir,
Remdesivir,Tocilizumab,Isavuconazole,Casirivimab + Imdevimab,2-Deoxy
D-Glucose,Molnupiravir
➢ Med Manor, Micro Labs & Linux Labs has participated in market
restatement in Jun’22 dataset

➢ Market restatement window is closed for this year

IQVIA TSA & SSA Dataset Jun'22 23